Figure 3From: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialSerial spirometry results on Day 1 (a) and at Weeks 12 (b) and 26 (c). All timepoints are statistically significant (p < 0.01).Back to article page